Can weight-loss drugs and hormones make endometrial cancer surgery safer for obese women?
NCT ID NCT07462663
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a 28- to 54-week program of weight-loss medication (semaglutide), a hormone-releasing IUD, diet, and exercise is safe and feasible before surgery in women with early endometrial cancer and a BMI of 40 or higher. Eighty participants will be randomly assigned to either immediate surgery or the pre-surgery program. The goal is to see if the program reduces surgical risks without allowing the cancer to progress.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Semaglutide (weight-loss drug) and levonorgestrel IUD (hormonal device)
What this could lead to
If it works, this could point toward a safer, less invasive way to prepare for surgery in women with early endometrial cancer and severe obesity, potentially reducing surgical risks.
What could go wrong
This is a small pilot study (80 people) testing feasibility, not effectiveness. The pre-surgery delay could allow tumor progression, and the weight-loss drug may cause side effects like nausea or gastrointestinal issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••